AIM ImmunoTech (AIM) News Today $9.17 -0.19 (-1.99%) Closing price 07/11/2025 03:58 PM EasternExtended Trading$9.02 -0.16 (-1.73%) As of 07/11/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AIM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period AIM ImmunoTech Inc. Showcases Ampligen Research at U.S.-Poland Science and Technology Symposium 2025 - NasdaqJuly 3, 2025 | nasdaq.comAIM ImmunoTech Inc. (AIM) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comAIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology TherapiesJuly 2, 2025 | globenewswire.comAIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity RequirementsJune 20, 2025 | finance.yahoo.comAIM ImmunoTech Faces NYSE Noncompliance NotificationJune 20, 2025 | tipranks.comAIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity RequirementsJune 20, 2025 | globenewswire.comAIM ImmunoTech (NYSE:AIM) Shares Gap Up - Should You Buy?June 20, 2025 | marketbeat.comAIM ImmunoTech (NYSE:AIM) Trading Down 15.5% - Time to Sell?June 18, 2025 | marketbeat.comAIM ImmunoTech (NYSE:AIM) Sets New 1-Year High - Here's WhyJune 17, 2025 | marketbeat.comAIM ImmunoTech Resumes Trading on NYSE AmericanJune 17, 2025 | globenewswire.comAIM ImmunoTech granted U.S. patent for AmpligenJune 12, 2025 | msn.comAIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®June 12, 2025 | globenewswire.comAIM ImmunoTech Announces NYSE American Removal of Trading SuspensionJune 12, 2025 | globenewswire.comAIM ImmunoTech Inc.: AIM ImmunoTech Announces 1-for-100 Reverse Stock SplitJune 12, 2025 | finanznachrichten.deAIM ImmunoTech Announces 1-for-100 Reverse Stock SplitJune 11, 2025 | globenewswire.comAIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of ImmunologistsMay 8, 2025 | globenewswire.comAIM ImmunoTech Inc AIMIApril 19, 2025 | morningstar.comMAIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open MarketApril 7, 2025 | globenewswire.comAIM ImmunoTech Inc trading halted, news pendingApril 5, 2025 | markets.businessinsider.comNYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)April 4, 2025 | businesswire.comAIM ImmunoTech Announces NYSE American Notice of Delisting and AppealApril 4, 2025 | globenewswire.comAIM ImmunoTech Inc. (AMEX:AIM) Q4 2024 Earnings Call TranscriptApril 3, 2025 | msn.comQ4 2024 AIM ImmunoTech Inc Earnings CallApril 2, 2025 | finance.yahoo.comAIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call TranscriptApril 1, 2025 | seekingalpha.comAIM ImmunoTech made ‘significant strides’ over course of 2024March 27, 2025 | markets.businessinsider.comEarnings Preview For AIM ImmunoTechMarch 27, 2025 | benzinga.comAIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 27, 2025 | markets.businessinsider.comAIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceMarch 11, 2025 | globenewswire.comInsider Buying: AIM ImmunoTech Inc. (NYSE:AIM) CEO Acquires 83,334 Shares of StockMarch 5, 2025 | insidertrades.comAIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenzaFebruary 28, 2025 | globenewswire.comAIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing ComplianceFebruary 26, 2025 | globenewswire.comAIM ImmunoTech appoints Chemerow as an Independent DirectorFebruary 26, 2025 | msn.comAIM ImmunoTech Appoints David Chemerow to BoardFebruary 26, 2025 | tipranks.comAIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent DirectorFebruary 26, 2025 | globenewswire.comAIM ImmunoTech doses first subject in Phase 2 study of Ampligen, ImfinziFebruary 26, 2025 | markets.businessinsider.comAIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic CancerFebruary 25, 2025 | globenewswire.comAIM stock touches 52-week low at $0.13 amid market challengesFebruary 14, 2025 | msn.comAIM ImmunoTech to not proceed with offering pursuant to registration statementFebruary 11, 2025 | markets.businessinsider.comAIM ImmunoTech Releases Virtual Investor “What This Means Segment”February 11, 2025 | globenewswire.comAIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024February 11, 2025 | globenewswire.comAIM ImmunoTech announces follow-up clinical study of Ampligen with FluMistFebruary 8, 2025 | markets.businessinsider.comAIM ImmunoTech advances Ampligen for avian influenza vaccineFebruary 8, 2025 | msn.comAIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaksFebruary 7, 2025 | globenewswire.comAIM ImmunoTech announces Safety Committee approval to proceed with Phase 2February 5, 2025 | markets.businessinsider.comCornish Metals Inc ("Cornish Metals" or the "Company") (AIM/TSX-V: CUSN) Result of Retail OfferJanuary 31, 2025 | globenewswire.comCornish Metals Inc (AIM/TSX-V: CUSN) ("Cornish Metals" or the "Company") Result of FundraisingJanuary 28, 2025 | globenewswire.comAIM ImmunoTech files to sell units, no amount givenJanuary 23, 2025 | msn.comAIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID ConditionsJanuary 23, 2025 | globenewswire.comAIM ImmunoTech highlights new article on links between COVID-19, ME/CFSJanuary 22, 2025 | markets.businessinsider.comAIM ImmunoTech Highlights Higher Post-COVID Prevalence Of Myalgic Encephalomyelitis/Chronic FatigueJanuary 22, 2025 | markets.businessinsider.com Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address AIM Media Mentions By Week AIM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AIM News Sentiment▼0.001.00▲Average Medical News Sentiment AIM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AIM Articles This Week▼02▲AIM Articles Average Week Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SCYX News ENLV News NRSN News COEP News TPST News PASG News TENX News CARA News LSTA News CVKD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:AIM) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AIM Stock Alerts